Imagine trying to find the right key for a lock when you have thousands of similar-looking keys. This tool uses AI to group patients with rare muscle diseases based on their genetic and imaging data, acting like a high-tech sorting system. It helps doctors quickly identify the exact type of disease a person has so they can start the right treatment sooner.
Hereditary Neuromuscular Diseases are difficult to diagnose accurately, leading to delayed treatments and poor patient outcomes. Current methods lack a unified way to combine genetic, imaging, and pathology data for precise patient grouping.
The ATLAS Platform, a web repository and AI tool for patient stratification. It includes algorithms for noise filtration, feature extraction, and high-dimensional clustering of multi-omics data.
If you are a drug development firm dealing with high failure rates in clinical trials due to patient variety — this project developed a stratification tool that identifies precise patient groups. This allows for better planning of clinical trials and more targeted therapy development.
If you are a medical software provider dealing with fragmented diagnostic data — this project developed the ATLAS Platform that integrates genetic, MRI, and histopathologic data. This creates a comprehensive web repository for precise clinical characterization.
If you are a specialized diagnostic clinic dealing with low accuracy in rare disease identification — this project developed AI algorithms that can increase the diagnostic rate of HNMDs by 30%. This leads to faster patient management and improved standard-of-care.
Based on available project data, the CoMPaSS-NMD Atlas Platform is intended to be a cost-effective application with data remaining publicly available for the research and health community.
The project aims to create a universal AI-based tool for diagnostic stratification of Hereditary NeuroMuscular Diseases (HNMDs), suggesting a design intended for broad application across this disease category.
Based on available project data, the final outcome is a public AI-based Atlas Platform, though specific licensing terms for the underlying algorithms are not detailed.
The system integrates multi-omics data including genetic, Nuclear Magnetic Resonance, and histopathologic records from clinical centers across five different countries.
The project period runs from 2023-05-01 to 2027-04-30, indicating the platform and guidelines will be finalized by April 2027.
The consortium is well-balanced for commercialization, featuring a 25% industry ratio with 3 industrial partners (including 2 SMEs). It combines deep clinical expertise from 6 academic/clinical centers across 8 countries with specialized ICT and AI competencies, ensuring the tool is both medically valid and technically scalable.
Contact Università degli Studi di Modena e Reggio Emilia
Contact us to explore licensing opportunities for the ATLAS Platform algorithms.
